Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792218 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 930
- Enrollment target
NCT02792218 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 930 participants.
The verdict
NCT02792218, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 930 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Interventions
- DRUG Ofatumumab subcutaneous injection
- DRUG Teriflunomide-matching placebo capsules
- DRUG Teriflunomide capsule
- DRUG Matching placebo of ofatumumab subcutaneous injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 930 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02792218
The ClinicalTrials.gov registry entry for NCT02792218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 930 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ofatumumab subcutaneous injection is the first listed.
NCT02792218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02792218 about?
NCT02792218 is a clinical study titled "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis". To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
What is the current status of trial NCT02792218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 930 participants. The study started on 2016-09-20. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT02792218?
The interventions under investigation include: Ofatumumab subcutaneous injection (DRUG), Teriflunomide-matching placebo capsules (DRUG), Teriflunomide capsule (DRUG), Matching placebo of ofatumumab subcutaneous injections (DRUG).
Who is sponsoring clinical trial NCT02792218?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.